MedTrace Logo

DMT310-005 Topical in the Treatment of Acne Rosacea

NCT05108025 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2022-12-08

No results posted yet for this study

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.

Conditions

  • Acne Rosacea

Interventions

DRUG

Topical Powder

Topical Powder mixed with diluent

DRUG

Placebo Topical Powder

Placebo Topical Powder mixed with diluent

Sponsors & Collaborators

  • Dermata Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05108025 on ClinicalTrials.gov